Is Pfizer (PFE) Stock Undervalued Right Now?
Werte in diesem Artikel
While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued, leaving room for profits.On top of the Zacks Rank, investors can also look at our innovative Style Scores system to find stocks with specific traits. For example, value investors will want to focus on the "Value" category. Stocks with high Zacks Ranks and "A" grades for Value will be some of the highest-quality value stocks on the market today.One company to watch right now is Pfizer (PFE). PFE is currently sporting a Zacks Rank of #2 (Buy) and an A for Value. The stock is trading with P/E ratio of 7.71 right now. For comparison, its industry sports an average P/E of 14.81. PFE's Forward P/E has been as high as 12.11 and as low as 7.71, with a median of 10.36, all within the past year.PFE is also sporting a PEG ratio of 0.56. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. PFE's industry currently sports an average PEG of 1.14. Within the past year, PFE's PEG has been as high as 1.24 and as low as 0.56, with a median of 0.97.Value investors also love the P/S ratio, which is calculated by simply dividing a stock's price with the company's sales. Some people prefer this metric because sales are harder to manipulate on an income statement. This means it could be a truer performance indicator. PFE has a P/S ratio of 2.02. This compares to its industry's average P/S of 3.65.Finally, investors will want to recognize that PFE has a P/CF ratio of 8.71. This data point considers a firm's operating cash flow and is frequently used to find companies that are undervalued when considering their solid cash outlook. PFE's P/CF compares to its industry's average P/CF of 22.72. Over the past 52 weeks, PFE's P/CF has been as high as 43.59 and as low as 8.71, with a median of 15.02.Value investors will likely look at more than just these metrics, but the above data helps show that Pfizer is likely undervalued currently. And when considering the strength of its earnings outlook, PFE sticks out at as one of the market's strongest value stocks.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Übrigens: Pfizer und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.
Ausgewählte Hebelprodukte auf Pfizer
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Pfizer
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: Zacks
Nachrichten zu Pfizer Inc.
Analysen zu Pfizer Inc.
Datum | Rating | Analyst | |
---|---|---|---|
08.04.2025 | Pfizer Buy | Jefferies & Company Inc. | |
04.04.2025 | Pfizer Neutral | JP Morgan Chase & Co. | |
07.03.2025 | Pfizer Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
05.02.2025 | Pfizer Kaufen | DZ BANK | |
05.02.2025 | Pfizer Buy | Goldman Sachs Group Inc. |
Datum | Rating | Analyst | |
---|---|---|---|
08.04.2025 | Pfizer Buy | Jefferies & Company Inc. | |
05.02.2025 | Pfizer Kaufen | DZ BANK | |
05.02.2025 | Pfizer Buy | Goldman Sachs Group Inc. | |
04.02.2025 | Pfizer Buy | Jefferies & Company Inc. | |
17.12.2024 | Pfizer Buy | Jefferies & Company Inc. |
Datum | Rating | Analyst | |
---|---|---|---|
04.04.2025 | Pfizer Neutral | JP Morgan Chase & Co. | |
07.03.2025 | Pfizer Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
05.02.2025 | Pfizer Neutral | UBS AG | |
05.02.2025 | Pfizer Neutral | JP Morgan Chase & Co. | |
04.02.2025 | Pfizer Neutral | UBS AG |
Datum | Rating | Analyst | |
---|---|---|---|
03.05.2018 | Pfizer Verkaufen | DZ BANK | |
16.05.2017 | Pfizer Sell | Citigroup Corp. | |
27.11.2012 | Pfizer verkaufen | Hamburger Sparkasse AG (Haspa) | |
28.08.2012 | Pfizer verkaufen | Hamburger Sparkasse AG (Haspa) | |
10.01.2012 | Pfizer verkaufen | Hamburger Sparkasse AG (Haspa) |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Pfizer Inc. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen